Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

• Published in: Mayo Clinic proceedings Vol. 82; no. 2; pp. 196 - 202
• Main Authors: Raveendran, Ganesh, MD, Ting, Henry H., MD, Best, Patricia J., MD, Holmes, David R., MD, Lennon, Ryan J., MS, Singh, Mandeep, MBBS, Bell, Malcolm R., MBBS, Long, Kirsten Hall, PhD, Rihal, Charanjit S., MD
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 2007
• Subjects: Internal Medicine; ADMIRAL; Abciximab and Carbostent Evaluation; Abciximab Before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up; ISAR-2; ACE; OR; CI; myocardial infarction; Intracoronary Stenting and Antithrombotic Regimen; odds ratio; CADILLAC; percutaneous coronary intervention; RAPPORT; TIMI; PCI; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications; Thrombolysis in Myocardial Infarction; confidence interval; ReoPro and Primary PTCA Organization and Randomized Trial; MI

OBJECTIVE To compare outcomes among patients receiving eptifibatide or abciximab during primary percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) with ST elevation or new left bundle branch block. PATIENTS AND METHODS From January 1999 through January 2004, 576 patients u...